CorMedix Inc.
CRMDDrugs in Pipeline
3
Phase 3 Programs
2
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
How CRMD's past catalysts played out
(taurolidine and heparin) catheter lock solution
Central Line Associated Blood Stream Infections (CLABSI)
Neutrolin
Kidney Failure, Chronic
CRMD-001-Deferiprone
Contrast-Induced Acute Kidney Injury
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
(taurolidine and heparin) catheter lock solution | Phase 3 | Central Line Associated Blood Stream Infections (CLABSI) | - | - |
Neutrolin | Phase 3 | Kidney Failure, Chronic | - | - |
CRMD-001-Deferiprone | Phase 2 | Contrast-Induced Acute Kidney Injury | - | - |
Frequently asked questions
What is in CorMedix Inc.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in CorMedix Inc.'s (CRMD) pipeline across Phase 3, Phase 2. Its lead program is (taurolidine and heparin) catheter lock solution (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is CorMedix Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for CorMedix Inc. (CRMD) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track CRMD biotech catalysts?→
Add CRMD to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow CorMedix Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.